Summary financial statements

Summary financial statements
SUMMARY CONSOLIDATED INCOME STATEMENT	2005 £m	Growth CER%	2004 £m
Turnover
Pharmaceutical	18,661	8	17,100
Consumer Healthcare	2,999	2	2,886
Total turnover	21,660	7	19,986
Cost of sales	(4,764)	8	4,360
Gross profit	16,896	7	15,626
Selling, general and administration	(7,250)	-	(7,201)
Research and development	(3,136)	8	(2,904)
Other operating income	364		235
Operating profit	6,874	16	5,756
Finance income	257		176
Finance costs	(451)		(362)
Share of after tax profits of associates and joint ventures	52		60
Profit on disposal of interest in associates	-		149
Profit before taxation	6,732	13	5,779
Taxation	(1,916)		(1,757)
Profit after taxation for the year	4,816	17	4,022
Profit attributable to minority interests	127		114
Profit attributable to shareholders	4,689		3,908
	4,816		4,022
Basic earnings per share (pence)	82.6p	18	68.1p
Diluted earnings per share (pence)	82.0p		68.0p

SUMMARY CONSOLIDATED BALANCE SHEET	2005 £m	2004 £m
Total non-current assets	14,021	12,164
Total current assets	13,177	10,780
Total assets	27,198	22,944
Total current liabilities	(9,511)	(8,564)
Total non-current liabilities	(10,117)	(8,443)
Total liabilities	(19,628)	(17,007)
Net assets	7,570	5,937
Shareholders' equity	7,311	5,724
Minority interests	259	213
Total equity	7,570	5,937

SUMMARY CONSOLIDATED CASH FLOW STATEMENT	2005 £m	2004 £m
Net cash inflow from operating activities	5,958	4,944
Net cash outflow from investing activities	(1,660)	(920)
Net cash outflow from financing activities	(2,914)	(3,407)
Increase in cash in the year	1,384	617
Exchange adjustments	233	(93)
Cash and bank overdrafts at beginning of year	2,355	1,831
Cash and bank overdrafts at end of year	3,972	2,355
Cash and bank overdrafts at end of year comprise:
Cash and cash equivalents	4,209	2,467
Overdrafts	(237)	(112)
	3,972	2,355

SUMMARY CONSOLIDATED INCOME STATEMENT